A clinical-stage biopharmaceutical developer of oral treatments for metabolic diseases with significant cash inflows from equity issuance supporting its research pipeline.
Investors may view this stock as a high-risk/high-reward play on the booming obesity drug market, betting that Corbus will successfully transition from clinical trials to commercialization soon. The substantial cash reserves totaling over $149M provide a runway to advance their pipeline without immediate need for further dilution in current market conditions.
The stock carries extreme risk due to zero revenue and a massive accumulated deficit, meaning the company must continue raising capital indefinitely to survive any clinical setbacks. The heavy reliance on equity financing suggests that if future cash flow from operations does not turn positive quickly, shareholder value will be significantly eroded through continued dilution.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation oral therapies for the treatment of metabolic diseases such as obesity and type 2 diabetes. The company operates primarily in the United States but maintains a global research and development pipeline aimed at addressing unmet medical needs in high-prevalence conditions. With no current revenue, the firm relies heavily on capital raising activities to fund its extensive R&D efforts.
Management successfully secured $166.6M in net cash flow from financing activities during the period, primarily driven by a massive $182.1M issuance of common shares, which helped offset the $41.8M net cash outflow from operations. Despite operating losses of $40.2M driven by $32.2M in R&D spending and $16.5M in G&A expenses, the company maintained a healthy liquidity position with ending cash and equivalents of $17.9M and marketable securities of $131.9M.
The metabolic disease sector is experiencing unprecedented growth driven by patient demand for oral alternatives to injectable GLP-1 agonists and advancements in small molecule therapeutics. However, the industry remains capital intensive with high barriers to entry regarding regulatory approval and clinical trial success rates for novel mechanisms of action.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $39.8M | $45.1M | $48.7M |
| Operating Income | $-39.8M | $-45.1M | $-48.7M |
| R&D | $16.1M | $31.2M | $32.2M |
| G&A | $18.7M | $13.9M | $16.5M |
| Stock-Based Comp | $5.7M | $3.5M | $6.1M |
| D&A | $763.0K | $640.6K | $588.0K |
| Depreciation | $763.0K | $641.0K | $600.0K |
| Other OpEx | $5.0M | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Pre-Tax Income | $-39.8M | $-45.1M | $-48.7M |
| Income Tax | $2.5M | $-474.0K | $-8.5M |
| Continuing Ops | $-42.3M | $-44.6M | $-40.2M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-42.3M | $-44.6M | $-40.2M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-42.3M | $-44.6M | $-40.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $60.2M | $23.5M | $153.0M |
| Cash & Equivalents | $17.0M | $13.7M | $17.2M |
| Marketable Securities | $42.2M | $7.2M | $131.9M |
| Prepaid Expenses | $791.6K | $2.4M | $3.6M |
| Other Current Assets | $192.5K | $192.5K | $285.0K |
| Long-Term Assets | $6.1M | $4.7M | $2.9M |
| PP&E (Net) | $1.6M | $973.2K | $385.0K |
| Operating Leases | $3.9M | $3.1M | $2.1M |
| Other LT Assets | $632.8K | $690.2K | $385.0K |
| Total Assets | $66.3M | $28.3M | $155.9M |
| Current Liabilities | $12.6M | $31.9M | $11.8M |
| Accounts Payable | $2.2M | $3.2M | $4.8M |
| Current Debt | $2.8M | $15.9M | — |
| Current Leases | $1.3M | $1.4M | $1.6M |
| Other Current Liab | $390.2K | $340.1K | $0 |
| Long-Term Liabilities | $20.7M | $3.3M | $1.6M |
| Long-Term Debt | $16.0M | $0 | — |
| LT Operating Leases | $4.7M | $3.2M | $1.6M |
| Other LT Liab | $22.2K | $44.4K | $0 |
| Total Liabilities | $33.3M | $35.2M | $13.5M |
| Shareholders' Equity | $33.0M | $-6.9M | $142.4M |
| Paid-In Capital | $425.2M | $429.8M | $619.3M |
| Retained Earnings | $-392.1M | $-436.7M | $-476.9M |
| AOCI | $-126.1K | $-1.6K | $35.0K |
| Total L&E | $66.3M | $28.3M | $155.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-42.3M | $-44.6M | $-40.2M |
| Non-Cash Adjustments | $10.6M | $915.4K | $1.4M |
| Working Capital Changes | $-5.8M | $7.6M | $-3.0M |
| Cash from Operations | $-37.5M | $-36.1M | $-41.8M |
| Capital Expenditures | $13.4K | $0 | — |
| Cash from Investing | $30.1M | $35.6M | $-121.3M |
| Debt Issuances | $1.4M | — | — |
| Cash from Financing | $-533.6K | $-2.8M | $166.6M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-8.0M | $-3.3M | $3.5M |
| Beginning Cash | $25.7M | $17.7M | $14.4M |
| Ending Cash | $17.7M | $14.4M | $17.9M |
The company's operations are concentrated in two primary areas: early-stage drug discovery and development targeting metabolic conditions, and strategic licensing or collaboration arrangements that may provide future revenue streams. Currently, all financial activity is directed toward Research and Development ($32.2M) and General & Administrative expenses ($16.5M) with no commercial revenue generated yet.
The company faces high risk of dilution as it consistently raises significant capital through equity issuance to fund operations without generating commercial revenue. There is a substantial retained earnings deficit of $476.9M indicating historical losses and a heavy reliance on external funding which may not be sustainable if market conditions tighten. Clinical trial failures or regulatory rejections could result in total loss of the current cash position, given the lack of diversified income sources.
The company possesses a specialized intellectual property portfolio focused on novel oral mechanisms of action for metabolic diseases, differentiating it from injectable-only competitors in the obesity market. Its ability to secure substantial capital through common share issuances ($182.1M) and cash flow from financing ($166.6M) provides the liquidity necessary to advance multiple clinical programs simultaneously.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.